Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Witt

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 17, 2012
Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreakMaxwell A Witt, Paul H Katz, David J Witt
The American Journal of Nursing|July 28, 2017
Good Nursing Is Good Antibiotic StewardshipRita D Olans, Richard N Olans, David J Witt
American Journal of Infection Control|December 12, 2018
Reasons for rejection of abstracts submitted to the Annual Conference of the Association for Professionals in Infection Control and Epidemiology: Ensuring transparency and encouraging qualityJoseph M Scaletta, James Davis, Charu Malik, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 15, 2013
Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohortMaxwell A Witt, Larry Arias, Paul H Katz, et al.
Drugs|January 13, 2017
Eight- or 12-Week Treatment of Hepatitis C with Ledipasvir/Sofosbuvir: Real-World Experience in a Large Integrated Health SystemJennifer B Lai, Maxwell A Witt, Mary Patricia Pauly, et al.
The Journal of Infection|August 31, 2024
IFNL4 genotype and other personal characteristics to predict response to 8-week sofosbuvir-based treatment for chronic hepatitis CThomas R O'Brien, David J Witt, Varun Saxena, et al.
Open Forum Infectious Diseases|March 5, 2020
Life Expectancy of Insured People With and Without Hepatitis C Virus Infection, 2007-2017Julia L Marcus, Leo B Hurley, Scott Chamberland, et al.
International Journal of STD & AIDS|May 4, 2019
Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare systemJennifer O Lam, Leo B Hurley, Scott Chamberland, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 15, 2018
No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black PatientsJulia L Marcus, Leo B Hurley, Scott Chamberland, et al.
Public Health Reports (Washington, D.C. : 1974)|May 12, 2018
Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured PopulationJulia L Marcus, Leo B Hurley, Scott Chamberland, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 17, 2012
Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreakMaxwell A Witt, Paul H Katz, David J Witt
The American Journal of Nursing|July 28, 2017
Good Nursing Is Good Antibiotic StewardshipRita D Olans, Richard N Olans, David J Witt
American Journal of Infection Control|December 12, 2018
Reasons for rejection of abstracts submitted to the Annual Conference of the Association for Professionals in Infection Control and Epidemiology: Ensuring transparency and encouraging qualityJoseph M Scaletta, James Davis, Charu Malik, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 15, 2013
Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohortMaxwell A Witt, Larry Arias, Paul H Katz, et al.
Drugs|January 13, 2017
Eight- or 12-Week Treatment of Hepatitis C with Ledipasvir/Sofosbuvir: Real-World Experience in a Large Integrated Health SystemJennifer B Lai, Maxwell A Witt, Mary Patricia Pauly, et al.
The Journal of Infection|August 31, 2024
IFNL4 genotype and other personal characteristics to predict response to 8-week sofosbuvir-based treatment for chronic hepatitis CThomas R O'Brien, David J Witt, Varun Saxena, et al.
Open Forum Infectious Diseases|March 5, 2020
Life Expectancy of Insured People With and Without Hepatitis C Virus Infection, 2007-2017Julia L Marcus, Leo B Hurley, Scott Chamberland, et al.
International Journal of STD & AIDS|May 4, 2019
Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare systemJennifer O Lam, Leo B Hurley, Scott Chamberland, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 15, 2018
No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black PatientsJulia L Marcus, Leo B Hurley, Scott Chamberland, et al.
Public Health Reports (Washington, D.C. : 1974)|May 12, 2018
Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured PopulationJulia L Marcus, Leo B Hurley, Scott Chamberland, et al.
Pageof 1